Moch H, Presti J C, Sauter G, Buchholz N, Jordan P, Mihatsch M J, Waldman F M
Department of Laboratory Medicine, University of California San Francisco 94143-0808, USA.
Cancer Res. 1996 Jan 1;56(1):27-30.
The clinical behavior of renal cell carcinoma (RCC) cannot be predicted by histological and other markers. In this study, comparative genomic hybridization was used to evaluate whether the number of genomic aberrations has prognostic significance in 41 nonmetastatic clear cell RCC extending beyond the renal capsule. Losses were most prevalent at 3p (56%) and 9p and 13q (24% each). The number of DNA losses per tumor was associated with recurrence-free survival (P = 0.03). DNA gains most often involved chromosome 5q (17%) and chromosome 7 (15%). The number of DNA gains was not associated with clinical outcome. Loss of chromosome 9p was the only individual locus associated with recurrence (P = 0.04), suggesting that a tumor suppressor gene on chromosome 9p may play a role in RCC progression.
肾细胞癌（RCC）的临床行为无法通过组织学及其他标志物进行预测。在本研究中，采用比较基因组杂交技术评估基因组畸变数量在41例超出肾包膜的非转移性透明细胞RCC中是否具有预后意义。缺失最常见于3p（56%）、9p和13q（均为24%）。每个肿瘤的DNA缺失数量与无复发生存期相关（P = 0.03）。DNA增益最常涉及5q染色体（17%）和7号染色体（15%）。DNA增益数量与临床结局无关。9p染色体缺失是唯一与复发相关的单个位点（P = 0.04），提示9p染色体上的一个肿瘤抑制基因可能在RCC进展中发挥作用。
